AV-203 is a monoclonal antibody that selectively targets the receptor ERBB3 and inhibits its activity. This receptor is expressed in many human cancers and is associated with cancer growth and survival and in development of resistance to anti-cancer agents. In this Phase I study AV-203 is administered intravenously once every 2 weeks in patients with metastatic or advanced solid tumors.
BAX69 is an anti-macrophage migration inhibitory factor (anti-MIF) antibody. MIF is a pro-inflammatory cytokine that is up-regulated in many human cancers and contributes to growth, angiogenesis and migration of cancer cells. BAX69 is administered intravenously every 2 weeks in a 28 day cycle in patients with malignant solid tumors.
IMGN853 is an immunoconjugate consisting of the humanized monoclonal antibody against folate receptor 1 (FOLR1) conjugated to the cytotoxic maytansinoid DM4. It is administered once every 21 days intravenously in patients with advanced solid tumors with FOLR1 expression. Tumor types which have a high incidence of FOLR1 positivity (serous or endometroid epithelial ovarian cancer, serous endometrial cancer, NSCLC of adenocarcinoma and bronchoalveolar cancer and clear cell renal carcinoma) can enroll without the specific testing.
LDE225 is an oral selective Smo antagonist that downregulates the Hedgehog signal transduction pathway. In this Phase I study the patients with advanced solid tumors receive LDE225 with Warfarin or Bupropion to evaluate the drug-drug interaction.
MSC1936369B is a MEK1/2 inhibitor and SAR245409 is a dual inhibitor of PI3K and mTOR. Both these oral drugs are administered daily in patients with advanced or metastatic KRAS and NRAS mutated non-small cell lung cancer, KRAS and PIK3CA mutated colon cancer, triple negative breast cancer and BRAF mutated melanoma patients.
RO5429083 is a humanized monoclonal antibody that binds to CD44, a transmembrane glycoprotein that is expressed in many cells, but what seems to have a more critical role in malignant growth. It is given as an IV infusion once every 2 weeks in patients with metastatic and/or advanced solid tumors that express CD44.